RESEARCH ARTICLE

Development of Enteric-Coated Tablet with a Unique Combination of Therapeutic and Nutraceutical Actives to Treat Colitis

Manish Kumar Gupta[1], Ketaki Dhane[2*], Chandraprabhu Jangme[2], Abhinandan Patil[2]

[1]*Jaipur School of Pharmacy, Maharaj Vinayak Global University, Jaipur, Rajasthan, India.*
[2]*D.Y. Patil College of Pharmacy, D.Y. Patil Education Society (Deemed to be University), Kolhapur, Maharashtra, India*

Received: 04th May, 2023; Revised: 25th May, 2024; Accepted: 08th June, 2024; Available Online: 25th June, 2024

ABSTRACT

The primary objectives of the current investigation were to design and characterize enteric-coated oil of ginger tablets in coconut water powdered form as a therapy for ulcerative colitis. One source that is both anti-inflammatory and high in electrolytes is a combination of ginger oil and powdered coconut water. By reducing inflammation and improving electrolyte and water balance, this combination will hasten the healing process. Starch 1500, microcrystalline cellulose, and ethyl cellulose were used to create enteric-coated tablets of ginger oil alone and in combination with coconut water powder. The results corroborated the findings that there were no unique interactions between any of the substances, as demonstrated by the examination of both tablets, which included morphology, micrometric features, and fourier transform infrared (FTIR) spectroscopic capabilities. We studied the dissolving characteristics of coated tablets at pH 1.2, 6.8, and 7.4 in a buffer. Quantification of gingerol was accomplished by use of reverse-phase high-performance liquid chromatography (RP-HPLC) technology. The selected formulation's therapeutic efficacy was lastly confirmed using a colitis model generated by 2,4,6-trinitrobenzene sulfonic acid. Tablets containing either ginger oil or a powdered combination of ginger oil as well as coconut water were compared in the research. Myeloperoxidase, lipid peroxidase, and histological assessment were calculated using the colitis model. The colon/body weight ratio was also measured. Research on animals has shown that a combination of the coated oil of ginger and the oil of coconut tablets, as opposed to ginger oil tablets alone, considerably improved the sick conditions in Wistar rats. The gain in weight and clinical improvements in the macroscopic and microscopic factors of induced colitis served as evidence of this. These results demonstrate the potential of coated tablets formulated with coconut water powder for the targeted delivery of ginger oil to the colon as well as for the improvement of colon health through the balance of micronutrients and water content. It is not practical to increase the dosage to compensate for metabolic loss while using ginger oil because of its strong taste and strength. Therefore, the formulation of choice is enteric coating. As enteric coating tablets target the intestine as the site of action, it is possible to use less potent ginger oil. Due to the inclusion of coconut water powder, the formulation not only helps cure the illness state but also promotes and supports a speedy recovery.

Keywords: Ginger oil, Coconut water, Enteric coating.

International Journal of Drug Delivery Technology (2024); DOI: 10.25258/ijddt.14.2.42

How to cite this article: Gupta MK, Dhane K, Jangme C, Patil A. Development of Enteric-Coated Tablet with a Unique Combination of Therapeutic and Nutraceutical Actives to Treat Colitis. International Journal of Drug Delivery Technology. 2024;14(2):886-894.

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

IBD, also known as inflammatory bowel disease, is characterized by ulcerative colitis, which mostly influences the gastrointestinal tract (large intestine), including the rectum. Chronic inflammation and ulceration in the rectum and colon lining are hallmarks of this condition. It is believed that a mix of hereditary, environmental, in addition, immune-mediated variables lead to ulcerative colitis. However, the precise etiology is yet unknown.[1]

As a result of inflammation, the mucosa lining the colon and genital region (rectum) are damaged in ulcerative colitis. This chronic inflammation leads to swelling, redness, and damage to the tissues. Over time, the inflammation can cause the formation of ulcers, which are open sores or lesions on the mucosal surface.

It's important to note that chronic inflammation in ulcerative colitis is not solely restricted to the gut; it can have systemic effects on other parts of the body. Moreover, long-term inflammation can contribute to the development of complications over time. Managing inflammation effectively is a key aspect of treating and managing ulcerative colitis, intending to achieve and maintain remission, improving

**Author for Correspondence: archupharma21@gmail.com*

the superiority of lifespan, and minimizing the danger of complications. It is important for people with ulcerative colitis to collaborate closely with their doctors in order to come up with a thorough treatment plan that takes into account inflammation and other aspects of the condition.[2]

The colon, or large intestine, maybe the site of a persistent illness called ulcerative colitis. Pain, bloody diarrhea, loss of weight, fever, and also anemia are the main indications. The causes are unknown. Theories are as follows: -

- Immune system dysfunction.
- Genetic
- Changes in the normal weight of bacteria.
- Environmental factor.[3]

Treatment Involved Includes

Amino salicylates such as mesalzine, sulphasalzine, steroids, immunosuppressants, and azathioprine 200 to 400 people per 10000 people per year. Ulcerative colitis has a greater prevalence in adults. Among the most common signs are bleeding from the rectal and diarrhea. A feeling of fatigue, fever, weight loss, anemia, and other signs. Additional symptoms of ulcerative colitis include pain in the joints, inflammation of the eyes, and stones in the kidneys.[4] Although symptoms, including high fever, may not go away throughout therapy, the duration of treatment might be months otherwise even years. It may be challenging for doctors to determine the efficacy of a specific cause or therapy for ulcerative colitis due to the disorder's variable etiology.

Depending on the site and degree of inflammation, multiple kinds of colitis can be distinguished.[5]

Ulcerative Proctitis

Anus (rectum) inflammation may lead to hemorrhage from the rectum (Symptoms mild).

Protosigmoiditis

(Called sigmoid colon), Including the bottom part of the colon and the rectum causes cramping in the abdomen and blood throughout the stool.

Left-sided Colitis

In left-sided colitis, the inflammation starts in the rectum and moves up the sigmoid and growing colon, as the name implies.

Universal Colitis (Pancolitis)

When the whole colon, including the right and left sides, the transverse colon, and the rectum, is inflamed, it is called universal colitis. Diarrhea with blood and stomach ache are concerns. Left side and unintended weight deficit.[6]

Serious Complications Include

- Major hemorrhage
- Abdominal perforation
- constriction of the colon
- Extremely low fluid levels -dehydration
- Arthritis, which is the swelling of the joints
- Inflammation of skin.[7]

Comparing Ulcerative Colitis with Crohn's Disease

The signs and characteristics of Crohn's disease and ulcerative colitis are remarkably comparable. All of the mentioned inflammatory bowel diseases affect various parts of the digestive system, although they manifest in numerous manners, as represented in Table 1.

Ayurvedic Perspective and Management of Ulcerative Colitis

The Ayurvedic method of treatment and health maintenance relies on natural substances. In Ayurveda medicine, proper digestion is considered crucial to overall health. Whenever the digestive tract isn't working properly, it causes the body to cool down, which blocks blood flow and makes it harder for toxins to leave the body. That means there will be a tridosha problem with Vata Pitta & Kapha.[8]

Our carbohydrate and fat molecules are metabolized through the Krebs cycle, ETC pathway. Due to fatty metabolism, our body system is unable to metabolize the generated free radicals and superoxide molecules due to a lack of several enzymes responsible for metabolism. These free radicals also stress and certain foods can trigger symptoms.[9]

Under Ayurvedic principles, ulcerative colitis may be looked at as pittajja grahini. Ayurveda working principle has based upon the tridosha pattern these are normal, then no issue. According to Sanskrit sholka when the pitta dosha gets imbalanced in the vitals intestine and causes pittajja grahini All metabolic processes, digestion, absorption, and transformation rely on Pitta energy.[10] Pitta carried out the entirety enzymatic as well as endocrine functioning. Pitta is described as warm, swift, transparent, somewhat greasy, and smells like flesh. It spreads easily. Pittajja grahani illness is caused by mandagi, which means bad digestion and appearance.[11]

The characteristic sign of ulcerative colitis is pitajja grahini, and severe inflammation is caused by excessive vitiation of pitta. Active phase flare-up symptoms include rectal bleeding and ulceration.[12]

So according to this sholk which is included in the classical Ayurvedic principles outlined in charka samhita provides a highly advantageous medical care for ulcerative colitis. In our study, we targeted the healing of the ulcerative ulcer as well as the restoration of normal colon functioning and maintenance of digestive digestive system wellness as a whole.[13]

Ginger rhizome from the Zinzibereace family is one of the most commonly used species and herbs. Ginger has many active phenolic compounds such as shagol, ginger, and zingerone. These compounds have anti-inflammatory antioxidative and immunomodulatory properties and gastroprotective effects.[14]

GIT effect – ginger has been traditionally used for GIT discomfort including nausea and indigestion, So the research is mainly focused on ginger oil- most of the studies used ginger extract and ginger powder.[15] Ginger and ginger oil demonstration potential more investigation is desirable to establish their efficiency and safety for managing ulcerative colitis. Coconut water and its powdered form can offer some potential benefits for individuals with ulcerative colitis.[16]

Table 1: Reviewing Crohn's disease and ulcerative colitis side by side

Crohn's disease: - It could potentially impact any portion of the gastrointestinal system, spanning from the point of entry to the anus. Particularly capable of influencing the total intestinal wall thickness.	Ulcerative colitis: - The inner membrane of the large gastrointestinal tract is the only structure that the colon (and sometimes the large intestine) may influence.

Table 2: Levels of Crospovidone and MCC

Factor	*Name*	*Unit*	*Concentration of Ginger and TCW (5:10) mg*		
			Low	*Medium*	*High*
Binder 1	Crospovidone	(mg)	10	15	20
Binder 2	MCC	(mg)	10	20	30

Due to its hydrating properties and nutrient content. Table 2 gives the concentration of binder in the formula. As ulcerative colitis can treat diarrhea which leads to fluid loss and dehydration coconut water powder contains electrolytes like potassium sodium, and magnesium which are important for maintaining proper fluid balance and electrolyte levels in the body.[17]

Tender Coconut – *Cocos nucifera* Arecaceae family

Electrolyte replacement: -Nutrient intake – essential vitamins, minerals, and antioxidants. Gentle on the stomach provides hydration without providing additional irritation important for those individuals with sensitive digestive systems due to ulcerative colitis.[18] In ulcerative colitis the inflammation disturbs the inner lining mucous membrane of the rectum and colon it can have systemic effects on other parts of the body managing inflammation effectiveness is a key aspect of treating and managing ulcerative colitis. Ginger oil and coconut powder are combined to create an anti-inflammatory and electron-rich source. By reducing inflammation and improving electrolyte balance this combination will fasten the healing process, so a study is planned to address the inflammation and other aspects of ulcerative colitis.[19]

MATERIAL AND METHOD

The ginger tablet was prepared by direct compression method. The enteric-coated ginger tablet was prepared to release medicaments in the intestine. These tablets have a special coating that resists dissolution in the acidic location of the small intestine. This would be protecting sensitive medications, minimizing stomach irritation, optimizing absorption time, release formulation, sustained release, extended-release, and reducing side effects.[20]

Formula for Preparation of Enteric-coated Mini-tablet.

Mini-tablet

Solid dosage form with a diameter less than equal to 3 mm and broken down into its component parts, the conventional tablet manufacturing process is very identical to the standard tablet. The primary distinction is that the person with swallowing difficulties and who is getting multiple drugs can benefit from the use of several punches, which reduce fluctuations within the medication release characteristics thus offering a more effective treatment.[21]

Mini-tablets are beneficial over the regular tablets of single unit dosage form. Mini-tablets can provide diverse release schemes that can be utilized together with numerous mixtures of mini tablets comprise.[22]

- Delayed release
- Immediate release
- Controlled release

The direct compression technique was utilized to make the tablets. Key components existed ginger as well as tender water from coconut (TCW) powdered form, crospovidone for disintegration, mass for dilution, and magnesium stearate for formulation lubrication. According to the experimental design, the amounts of the immediately compressible binding substances (MCC and copovidone) have been adjusted (low, medium, high) shown in Table 2.[23]

Microcrystalline cellulose (A vices pH- 10.2) binder- which produces robust granules that remain stable in the high shear environment, mannitol- Filter/binder- as well as a bulk sweetener.

Hypromellose – (Methocel K4M) (Hydroxy propyl methyl cellulose water-soluble thickener as a thickening agent for cooling and adhesion) Eudragit Rs-po – A permeable and cationic polymers used for coating. HPC klucel –EF as wetting agent. Colloidal SiO2 traditional glidant magnesium stearate as-lubricant.

Total weight of uncoated tablet with coating material per sustained release

Coating tablet with a number of layers

- First 5 layers with 5% EC-coating
- Next 3 layers with 10% EC-coating
- Last 2 layers with 15% EC-coating.

PH responsive minitablet

When it comes to the gastrointestinal system, the pH may vary substantially.

Stomach - 1.5 to 3

Duodenum- 4 to 5

Lower part of jejunum and ileum – 6.5 to 7.5

Colon- 5.6 to 6.9

Table 3 represents the factorial batches of quantity per unit. A pH-responsive releasing polymeric material, such as Eudragit, may be employed as a coating to facilitate medication absorption at specific GIT sites. Using the direct compression technique, ginger oil tablets have been produced. Each ingredient mentioned below in Table 4 was weighed accurately using an electronic weighing balance (AX 200, Shimadzu, Japan) and blended thoroughly with the use of a 'V' cone blender. A tablet punch with a diameter of 4 mm was attached to a multi-punch compressing device (Trover, Pharmamec, India) in order to compress the perfectly blended portions of powdered blend, Table 4 displays the formula for preparation of ginger tablets with coating material for sustained release & Table 5 represent Ginger Tablets with coating material layers for sustained release.[24]

Table 3: Factorial batches of tablet

Ingredients	*Factorial batches (quantity per unit dose in mg)*								
	1	2	3	4	5	6	7	8	9
	Ginger and TCW								
Extract	15	15	15	15	15	15	15	15	15
Binder 1	H	L	H	M	M	M	L	H	L
(MCC)	30	10	30	20	20	20	10	20	10
Binder 2	L	H	H	L	H	M	M	M	L
(Copovidone)	10	20	20	15	20	15	15	15	10
Crospovidone	25	25	25	25	25	25	25	25	25
Mg stearate	5	5	5	5	5	5	5	5	5
DCP	15	25	5	20	15	20	30	20	35
Total weight	100	100	100	100	100	100	100	100	100

Table 4: Formula for preparation of ginger tablets with coating material for sustained release

S. No.	*Ingredient*	*mg*
1	Ginger oil	5.00
2	Tender coconut water powder (TCWP)	10.00
3	Avicel PH 102(MCC)	4.00
4	Mannitol (Pearlitol sd100)	1.50
5	Hypromellose (Methocel K 4 M)	1.25
6	Eudragit RS PO	1.5
7	Hydroxypropyl cellulose Klucel EF	1
8	Colloidal silicon dioxide (Aerosil 200 Pharma)	0.25
9	Magnesium stearate	0.50
Total weight of uncoated tablet		25.00

Table 5: Ginger tablets with coating material layers for sustained release

	Coating Material with several layers									
Number of 5% ethyl cellulose coatings	1	2	3	4	5	-	-	-	-	-
Number of 10% ethyl cellulose coatings	-	-	-	-	-	1	2	3	-	-
Number of 15% ethyl cellulose coatings	-	-	-	-	-	-	-	-	1	2

Formulation Code F1

Evaluation of developed mini tablets

Several parameters were used to evaluate each compressed mini tablet after compression. Tests for assay, content and weight consistency, friability and hardness, tablet thickness, and diameter are all part of this.[25]

Weight variation

The uniform distribution of weight was tested by randomly selecting twenty mini tablets from each of the manufactured batches. The average weight was determined by placing them on an electronic scale. We measured and documented the percentage of weight fluctuation.[26]

Friability

The cylindrical container of the Roche Friabilator was loaded with 10 pre-weighed mini tablets, one from each of the manufactured batches. For four minutes, the friabilator was spun at a speed of 25 km/h. Once the allotted time had elapsed, the micro tablets were dusted with a microfiber towel, and their final weight was recorded. As an estimate of friability, the % reduction in weight was computed. We recorded the mean results after experimenting three-time.[27]

Hardness

Utilizing a Monsanto hardness tester, the typical breaking strength of micro tablets was determined. A strength test was conducted on ten mini tablets that were chosen at random. A recorded mean hardness response was obtained.[28]

Diameter and thickness

The developed mini tables have been evaluated for their average diameter and thickness utilizing a Vernier caliper. Three separate runs of the procedure were carried out, with each run recording the average mini tablet thickness and diameter.[24]

Disintegration test

One tablet was put in each of the six tubes (3 inches lengthy opened at the top) of the USP disintegration rate test equipment, which was positioned toward a 10-mesh screens towards the bottom of the last portion of the basket rack assembly. Then, the disk was placed on top of each tablet. In order to determine the disintegration time, add one tablet to each tube and set the basket rack in the medium at 37 ± 2°C. Make sure that the tablet stays 2.5 cm below the liquid's surface as it rises and stays no closer than 2.5 cm towards the beaker's base. The tablet-containing basket assembly is raised and lowered 5 to 6 cm at a rate of between 28 and 32 revolutions per minute by means of a conventional motor-driven device. The experiment

might potentially make use of plastic discs with perforations. You put them on top of your pills, and they will make them more abrasive. While the discs' significance and ability to increase test sensitivity are debatable, they do serve a purpose for floating tablets. Run the device for the allotted duration (15 minutes for an uncoated tablet, excluding any valid and allowed exceptions). Triplicate runs of the research were performed.[29]

Assay of mini tablets

Table 6 represents assay parameters of minitablet A volumetric flask with 5 mL of methanol is filled with an equivalent weight of 0.100 g of standard gingerol-6. The medicine was dissolved in methanol and then acetonitrile was added until the amount reached 100 mL. Take 1-mL of the stock solution that was made before and dilute it with acetonitrile until it reaches a volume of 10 mL. Testing the filtrate using high-performance liquid chromatography (HPLC) at 278 nm allowed us to assess the sample's drug concentration. It was determined what proportion of drugs were loaded.

Dissolution testing

A USP dissolving equipment II (paddle type) with a coated paddle that reduces stirring-induced turbulence was used. A variable-speed motor spins the paddle at a regulated pace, and it is mounted vertically to the motor.[30]

This apparatus was kept at a temperature of 37 ± 0.5°C and a spinning speed of 50 ± 4 rpm. For each of the six dissolving flasks, one little tablet containing a combination of ginger oil and delicate coconut water powder had been positioned at the base of the media-containing flask. A 200 mL solution of 0.1 N HCl buffers (pH 1.2) was used to evaluate the dissolution of the ginger oil tablets during the first 2 hours.[31] Phosphate buffer was then added until the amount of the dissolving medium reached 900 mL, ensuring that the pH remained at 6.8. The media covered the research for the next 3 hours. Each dissolving vessel had a 10-mL aliquot collected at 1, 2, 3, 4, 5, 6, 7, and 8 hours, respectively. In order to keep up the sink condition, the removed medium was replaced with new medium. The syringe screen (0.45 μm) was used to filter the extracted materials. The HPLC analysis was performed on the samples at 278 nm.[32]

Animal Study

Preparation of experimental colitis in mice[33]

To test the effects of TCWP on TNBS-induced colitis, the mice were assigned at random to one of four groups: control, TCWP-treated, mini-tablet, and TNBS-treated (without TCWP). Seven mice made up each group. One way to produce TNBS-induced colitis in anesthetized mice was to inject a 2.5% (w/v) the TNBS solutions (100 μL) in 50% ethanol into their colons using a tiny round-tip needle that was attached to a 1-mL syringe. The car was the only intervention for the control group. The point of the needle was introduced around three to 4 cm from the anal margin. Holding the mice vertically for 30 seconds after injection allowed the agents to disseminate throughout the whole colon and cecum. The technique resulted in the retention of the TNBS enema in more than 95% of the animals. The experiment was terminated if an animal passed the TNBS-ethanol solution too rapidly. For three days after TNBS therapy, take one small tablet orally once day with or without TCWP. The mice were killed the day after the last sample treatment. The colon was swiftly dissected, then gently washed with PBS to eliminate any feces. Colon tissue was utilized for immune blotting as well as ELISA analysis after a previously described scoring system was applied to the macroscopic evaluation of disease grade (0, no ulcer and no swelling; 1, no ulceration and regional hyperemia; 2, ulcers with hyperemia); 3, ulceration along with inflammation at a single location only; 4, two or more locations of ulceration and swelling; 5, ulceration expanding more than 2 cm).

Table 6: Assay of mini tablets

r. No.	*Parameters*	*Specifications*
1.	Composition of mobile phase	Acetonitrile: water in a ratio of 55:45 v/v
2.	Column specifications	Fortis C18 (100 x 4.6 mm id with 2.5 μm)
3.	Run time	About 30 minutes
4.	Flow rate	0.75 mL/min
5.	Detection at wavelength	278 nm
6.	Retention time	5.59 minutes
7.	Standard solution concentration	Gingerol-6, 10 mcg/mL
8.	Samples solution concentration	Mini tablet 100 mcg/mL
9.	Linearity range	5–125 mcg/mL

In preparation for the histological examination, the colons were soaked in a 30% solution of sucrose (in 50 mM phosphorus-buffered saline) and left at 4°C as long as sectioning. The fixation process took place overnight in a phosphate buffer solution (50 mM, pH 7.4) that included 4% paraformaldehyde. Colon sections were made from frozen specimens employing a cryostat (Leica Microsystems AG, Germany) in the coronal plane (10 μm) and then stained with hematoxylin-eosin.

Assay of myeloperoxidase activity

Over time, the absorbance at 650 nm was measured by incorporating 50 μL of the colon supernatant to a reaction mixture containing 1.6 mM tetra methyl benzidine as well as 0.1 mM Hydrogen peroxide. The mixture was then incubated at 37°C. The enzyme's ability to degrade 1 μmol/mL of peroxide at 37 °C was called myeloperoxidase activity, and it was measured in units per milligram of protein.

ELISA

An ELISA for IL-1β, IL-6, IL-10, and TNF-α was performed by homogenizing colons or cell-cultured the supernatants in one milliliter of ice-cold RIPA lysis buffer that included 1% protease inhibiting cocktail and 1% phosphatase inhibitory cocktail. Before being moved to 96-well ELISA plates, the

Table 7: Investigation of manufactured mini tablets with coating material for sustained release

Parameters	*CC1*
Average weight of powder (mg)	150 ±0.23
Weight variation (%)	0.10 ±0.11
Friability (%)	0.30 ±0.21
Hardness (Kg/cm^2)	0.56 ± 0.31
Diameters (mm)	8.98 ±0.25
Thickness (mm)	3.54 ±0.64
Disintegration test (hrs)	2.08 ± 0.44
Assay by HPLC	97.25 ±0.78



Figure 1: Dissolution study chromatogram



Figure 2: Graphical representation of percentage cumulative drug released from selected formulations using HPLC

lysate was centrifuged at 15,000 x g and 4°C for 15 minutes. Commercial ELISA kits from Pierce Biotechnology, Inc. in Rockford, IL, USA, were used to measure the quantities of IL-1², IL-6, IL-10, and TNF-α.[34]

Clinical and histological evaluation of colitis

As part of the clinical evaluation of TNBS-induced colitis, the weight of each mouse was routinely tracked. Postmortem clinical evaluation of parameters, including variation in colon weight and length across all treatment groups, was conducted using a complete colon sample. Histological and histomorphometric analyses were conducted to further evaluate the intestinal damage. After excising portions of colonic tissue that are 6 to 7 cm proximal to the rectum, which are cross-trimmed, the tissue is fixed for 24 hours in a solution of 10% neutral buffered formalin phosphate. Hematoxylin and eosin (H&E) staining and toluidine blue (TB) staining were



Figure 3: Histopathological study



Figure 4: Change in weight after treatment

employed to quantify the mast cell population microscopically in paraffin-embedded tissue slices (3–4 lm) in order to assess the amount of inflammation.[35] To determine the extent of fibrosis, Masson's trichome dye was applied to the transverse colonic sections.[36] Additionally, pathologists not familiar with the experimental groups evaluated colored colonic tissue specimens below light microscopy and assessed the histological characteristics. A scale was developed by.[35] and used to assess the microscopic characteristics.[37] Utilizing an automated image analyzer, morphometric analysis was conducted on areas covered by ulcerative lesions (%), number of infiltrating mast cells (cells/mm2 of fields), and inflammatory cells.

Statistical analysis

The average standard deviation is employed to represent all data, and a Student's t-Newman-Keuls test is used to examine statistical significance after a one-way ANOVA.[38]

RESULT AND DISCUSSION

Investigation of Manufactured Mini Tablets

Preparation and additional evaluation of the sustained-release tablets were carried out as shown in Table 7 done by performing a series of tests, including those measuring diameters, thickness, uniformity of weight, friability, hardness, disintegration test (min), assay, and dissolution.



Figure 5: Change in colon length after treatment



Figure 6: Histological microscopic score after treatment



Figure 7: Myeloperoxidase activity after treatment

Dissolution Study by HPLC Technique

From the above study CC1 was selected and further studied by the HPLC technique in Figures 1 and 2 display a graphical representation of the percentage cumulative drug released from selected formulations using HPLC.

Repressive Consequence of Mini Tablets on TNBS-Induced Colitis in Mice

The potential of tablets to prevent colitis in mice induced with TNBS was the next area of investigation. In addition to increasing myeloperoxidase activity and causing inflammatory cytokine changes, TNBS induced significant colonic inflammation, which manifested as colon shortening displayed in Figure 3. Treatment with mini tablets repressed myeloperoxidase activity and TNBS-induced colon shortening. Comparative analysis in graphical representation done in Figures 4-8. Anti-colitic effect of ginger oil; with TCWP was comparatively better than ginger oil without TCWP.



Figure 8 : Effect of samples on TNF-α cytokine production

Furthermore, mini tablets with TCWP also inhibited TNF-α, expressions in TNBS-induced colitis mice. Though, the blend increased IL-10 expression reduced by TNBS.[34]

DISCUSSION

Patients with ulceration colitis frequently experience inflammation in the colon, as well as the development of small, visible wounds of ulcers that exude pus and mucus. This inflammatory condition is known to impact the inner layer of the large intestine, specifically the rectum. Inflammation and lesion development work hand in hand to cause acute stomach pain, frequent colon emptying, and diarrhea. An antigenic trigger impairs the normal control of the immune system, leading to the prolonged activation of the mucosal immune response and inflammation, which is the fundamental pathophysiological concept underlying ulcerative colitis. There is a spectrum of severity in ulcerative colitis (mild, moderate, severe) that primarily affects and restricts therapy choices.

In both laboratory and animal studies, the anti-inflammatory effects of these ginger compounds with TCWP were significant.

Furthermore, it has been shown that amino acids had substantial therapeutic effects in UC management; this suggests that the anti-inflammatory effects may be attributed to ginger oil, while the synergistic qualities of TCWP are also present.

When evaluated using histopathological markers, the combined effects of ginger oil and TCWP were seen to significantly reduce the regulated inflammatory responses. The healing impact on illnesses is much better in the therapy group as well.

Minitablet TCWP showed lower MPO activity in this research. Combination that demonstrates the anti-inflammatory effects of the therapeutic minitablet and TCWP and displays the decreased neutrophil count in the tissues.

They were given TNBS diluted in ethanol to cause ulceration colitis. The initial epithelial breakdown was produced by the ethanol, and the transmural swelling of the colon was caused by the TNBS..

The examination of histopathology and histomorphology metrics in drug-induced colitis showed characteristics like the severity of the condition and the effectiveness of the mini-tablet containing TCWP in TNBS for recovery. These changes include:

- Cell depletion

- Mucous cell depletion
- Infiltration of inflammatory cells
- Neovascularization
- Collagen deposition
- Depletion of mucosal mast cells
- Edematous change

Reportedly, improper deposition of extracellular metris causes inflammation in ulcerative colitis, which in turn causes the buildup of abnormal fibrotic collagen. The obstructive symptomatology that results from this occurrence is a disruption of the normally occurring interaction involving mucus and the underlying layer of muscles. Supporting its therapeutic potential, histopathology investigation showed that TNBS-inflamed mice treated with a minitablet of ginger TCWP considerably decreased the deposition of aberrant collagen fibers.

Histomorphometry study showed that the number of mucosal mast cells in colon tissue decreased during UC induction. Among the mice used in the study. This suggests that inflammation is causing mast cell degranulation to occur less often. It is thought that the level of inflammation in UC patients is determined by proinflammatory cytokines such 1L-6 TNF - alpha. There is evidence that the severity of UC is correlated with changes in the expression levels of 1L-6 and TNF-alpha.

There seems to be a positive relationship between the cytokines that indicate the seriousness of UC. Studies have shown that the experimental mice's cytokine levels in their bladder tissues altered dramatically after receiving a combination of treatments, which might be due to the active ingredients in herbal formulations.

REFERENCES

1. Ryan Ungaro, Saurabh Mehandru, Patrick B Allen, Laurent Peyrin-Biroulet and JC. Ulcerative colitis Ryan HHS Public Access. Lancet. 2017;389(1):139–48. Available from: https://doi.org/10.1016/S0140-6736(16)32126-2
2. Jung SA. Differential diagnosis of inflammatory bowel disease: What is the role of colonoscopy? Clin Endosc. 2012;45(3):254–62.
3. Seyedian SS, Nokhostin F, Malamir MD. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life. 2019;12(2):113–22. Available from: https://doi.org/10.5946/ce.2012.45.3.254
4. Travis SPL, Stange EF, Lémann M, Øresland T, Bemelman WA, Chowers Y, et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohn's Colitis.2008;2(1):24–62. Available from:https://doi.org/10.1016/j.crohns.2007.11.002
5. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut. 2006;55(6):749–53. Available from: https://doi.org/10.1136%2Fgut.2005.082909
6. Raj VS, Mou H, Smits SL, Dekkers DHW, Müller MA, Dijkman R, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature [Internet]. 2013 Mar 14;495(7440):251–4. Available from: https://pubmed.ncbi.nlm. nih.gov/23486063. Available from: https://doi.org/10.1038/nature12005
7. Gupta, Manish Kumar, ketaki Dhane, Birendra Shrivasttva, Supriya Hyam, Sujit Nagare AP. A Review on Metabolic Syndrome. Int J Health Sci (Qassim). 2022;6(S2)(1):5866–5875. Available from: https://doi.org/10.53730/ijhs.v6nS2.6507
8. Ioniță-Mîndrican CB, Ziani K, Mititelu M, Oprea E, Neacșu SM, Moroșan E, et al. Therapeutic Benefits and Dietary Restrictions of Fiber Intake: A State of the Art Review. Nutrients. 2022;14(13):100–25. Available from: https://doi.org/10.3390/nu14132641
9. .Lim HH, Yang SJ, Kim Y, Lee M, Lim Y. Combined treatment of mulberry leaf and fruit extract ameliorates obesity-related inflammation and oxidative stress in high fat diet-induced obese mice. J Med Food. 2013;16(8):673–80. Available from: https://doi.org/10.1089/jmf.2012.2582
10. Kendall WA, Stringer WC. Physiological aspects of clover. Clover Sci Technol. 2015;31(3):111–59. Available from: https://doi.org/10.2134/agronmonogr25.c4
11. Sorathiya A, Vyas S, Bhat PS. A clinical study on the role of ama in relation to Grahani Roga and its management by Kalingadi Ghanavati and Tryushnadi Ghrita. AYU (An Int Q J Res Ayurveda). 2010;31(4):451. Available from: https://doi.org/10.4103/0974-8520.82041
12. Patel M, Patel K, Gupta S. Effects of Ayurvedic treatment on forty-three patients of ulcerative colitis. AYU (An Int Q J Res Ayurveda). 2010;31(4):478. Available from: https://doi.org/10.4103/0974-8520.82046
13. Pooja B, Bhatted S. Ayurvedic management of Pravahika – A case report. AYU (An Int Q J Res Ayurveda). 2015;36(4):410.
14. Mao QQ, Xu XY, Cao SY, Gan RY, Corke H, Beta T, et al. Bioactive compounds and bioactivities of ginger (zingiber officinale roscoe). Foods. 2019;8(6):1–21. Available from: https://doi.org/10.4103/0974-8520.190701
15. Nikkhah Bodagh M, Maleki I, Hekmatdoost A. Ginger in gastrointestinal disorders: A systematic review of clinical trials. Food Sci Nutr. 2019;7(1):96–108. Available from: https://doi.org/10.1002/fsn3.807
16. Ballester P, Cerdá B, Arcusa R, Marhuenda J, Yamedjeu K, Zafrilla P. Effect of Ginger on Inflammatory Diseases. Molecules. 2022;27(21). Available from: https://doi.org/10.3390/molecules27217223
17. Manish Kumar Gupta1, Ketaki Dhane 2* B, Shrivasttva3, Supriya Hyam4, Sujit Nagare5, Arvind Shinde6 AJ. Cell-Based Phenotypic Approaches in Drug Discovery. Int J Pharm Pharm Res. 2022;23(3):309–21.
18. Manish Kumar Gupta, Ketaki Dhane, Birendra Shrivasttva, Supriya Hyam, Sujit Nagare. Evaluation of the Impact of the Ayurvedic Formulation" Amruthotharam" on Obesity-Related Diabetic and Hepatic Disorders. Int J Res Pharm Sci. 2020;11(4):8194–200. Available from: http://dx.doi.org/10.26452/ijrps.v11i4.1813
19. Mashadi NS, Ghiasvand R, G A, M H, L D, Mofid MR. Antioxidative and Anti-Inflammatory Effects of Ginger in Health and Physical Activity: Review of Current Evidence. Int J Prev Med. 2013;36–42. Available from: https://api.semanticscholar.org/CorpusID:18384898
20. Gupta, Manish Kumar, ketaki Dhane, Birendra Shrivasttva, Supriya Hyam SN. SHADDHARANA CHURNA: A POLYHERBAL FORMULATION. Front Biosci. 2022;27(2022):80–8.
21. Timucin U. Mini Tablets: A Short Review-Revision. Open J Chem [Internet]. 2017 Jul 25;012–22. Available from: https:// www.

peertechzpublications.org/articles/OJC-3-107.php
22. Manish Kumar Gupta, Ketaki Dhane, Birendra Shrivasttva, Supriya Hyam, Sujit Nagare. UNI-Directional Double Run Multi-Marker Based Standardization of "Amruthothram" Ayurvedic Medicine by HPTLC. Int J Res Pharm Sci. 2020;11(4):8216–21. Available from: https://doi.org/10.26452/ijrps.v11i4.1817
23. Manish Kumar Gupta, Sujit Nagare, Birendra Shrivastava, Supriya Hyam, Ketaki Dhane. Preparation and Evaluation of Topical Polyherbal Emulgel Formulation for its Wound Healing Potential. Int J Res Pharm Sci. 2020;11(4):8181–6. Available from: https://doi.org/10.26452/ijrps.v11i4.1808
24. Manish Kumar Gupta, Sujit Nagare, Birendra Shrivastava, Supriya Hyam, Ketaki Dhane. Development and Evaluation of Topical Polyherbal Formulations for their Antimicrobial Potential. Int J Res Pharm Sci. 2020;11(4):8187–93. Available from: https://doi.org/10.26452/ijrps.v11i4.1812
25. Pharmaceutical EJ. Post-Compression Evaluation Parameters for Tablets-an. 2022;4(March):526–30.
26. Basu B, Bagadiya A, Makwana S, Vipul V, Batt D, Dharamsi A. Formulation and evaluation of fast dissolving tablets of cinnarizine using superdisintegrant blends and subliming material. J Adv Pharm Technol Res. 2011;2(4):266–73. Available from: https://doi.org/10.4103/2231-4040.90885
27. Saleem M, Shahin M, Srinivas B, Begum A. Evaluation of Tablets by Friability Apparatus. Int J Res Pharm Chem. 2014;4(4):837–40. Available from: https://api.semanticscholar.org/CorpusID:212487322
28. Mehmood Y, Shahid H, Abbas M, Farooq U, Ali S, Kazi M. Microsponge-derived mini tablets loaded with immunosuppressive agents: Pharmacokinetic investigation in human volunteers, cell viability and IVIVC correlation. Saudi Pharm J [Internet]. 2023;31(11):101799. Available from: https://doi.org/10.1016/j.jsps.2023.101799
29. USP-NF. The United States pharmacopeia <701> Disintegration. United States Pharmacopeial Conv [Internet]. 2023;stage 4:2–5. Available from: https://www.usp.org/sites/default/files/usp/document/harmonization/gen-chapter/april-2019-m99460.pdf
30. Slovesnova N V., Petrov AY, Glavatskih S, Bolotova V, Kopchuk DS. The Development of Tablets containing Vinpocetine and Ginkgo biloba L. Extract. Int J Drug Deliv Technol. 2023;13(4):1139–44. Available from: https://api.semanticscholar.org/CorpusID:267109325
31. Mali DP, Kamble SP, Gaikwad DT, Wadkar GH, Bhutkar MA, Tamboli FA, et al. Standardization and Evaluation of Herbal Antihypertensive Sarpagandha (Reserpine) Tablet Formulations. Int J Pharm Qual Assur. 2023;14(1):7–11. Available from: http://dx.doi.org/10.25258/ijpqa.14.1.02
32. Bai G, Armenante PM, Plank R V., Gentzler M, Ford K, Harmon P. Hydrodynamic investigation of USP dissolution test apparatus II. J Pharm Sci. 2007;96(9):2327–49. Available from: https://doi.org/10.1002/jps.20818
33. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98(3):694–702. Available from: https://doi.org/10.1016/0016-5085(90)90290-h
34. Jeong J ju, Jang SE, Joh EH, Han MJ, Kim DH. Kalopanaxsaponin B ameliorates TNBS-induced colitis in mice. Biomol Ther. 2012;20(5):457–62. Available from: https://doi.org/10.4062%2Fbiomolther.2012.20.5.457
35. Park SY, Ku SK, Lee ES, Kim JA. 1,3-Diphenylpropenone ameliorates TNBS-induced rat colitis through suppression of NF-κB activation and IL-8 induction. Chem Biol Interact [Internet]. 2012;196(1):39–49. Available from: https://www.sciencedirect.com/science/article/pii/S0009279712000294
36. Kim JY, Park BK, Park HJ, Park YH, Kim BO, Pyo S. Atopic dermatitis-mitigating effects of new Lactobacillus strain, Lactobacillus sakei probio 65 isolated from Kimchi. J Appl Microbiol. 2013;115(2):517–26. Available from: https://doi.org/10.1111/jam.12229
37. Regmi SC, Park SY, Ku SK, Kim JA. Serotonin regulates innate immune responses of colon epithelial cells through Nox2-derived reactive oxygen species. Free Radic Biol Med [Internet]. 2014;69:377–89. Available from: https://www.sciencedirect.com/science/article/pii/S089158491400080X
38. Zhao XP, Huang YY, Huang Y, Lei P, Peng JL, Wu S, et al. Transforming growth factor-B1 upregulates the expression of CXC chemokine receptor 4 (CXCR4) in human breast cancer MCF-7 cells. Acta Pharmacol Sin [Internet]. 2010;31(3):347–54. Available from: http://dx.doi.org/10.1038/aps.2009.204